Brought to you by 
Paladin Labs licenses Savene rights from SpePharm
01 Oct 2020
Executive Summary
Immediately after it received rights to the drug from TopoTarget, SpePharm Holding BV is licensing fellow spec pharma Paladin Labs exclusive rights to develop and sell Savene (dexrazoxane) in South Africa and Israel, a move that helps the Paladin greatly expand its international reach.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Paladin Labs licenses Savene rights from SpePharm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice